GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Forward PE Ratio

Pharmaron Beijing Co (SZSE:300759) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Forward PE Ratio?

Pharmaron Beijing Co's Forward PE Ratio for today is 0.00.

Pharmaron Beijing Co's PE Ratio without NRI for today is 21.89.

Pharmaron Beijing Co's PE Ratio for today is 23.39.


Pharmaron Beijing Co Forward PE Ratio Historical Data

The historical data trend for Pharmaron Beijing Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Forward PE Ratio Chart

Pharmaron Beijing Co Annual Data
Trend
Forward PE Ratio

Pharmaron Beijing Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Pharmaron Beijing Co's Forward PE Ratio

For the Biotechnology subindustry, Pharmaron Beijing Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Forward PE Ratio falls into.



Pharmaron Beijing Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Pharmaron Beijing Co  (SZSE:300759) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Pharmaron Beijing Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (SZSE:300759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines